【レポートの概要（一部）】
1. Report Overview
1.1 Global Dermatological Drugs: Market Overview
1.2 Global Dermatological Drugs Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. An Introduction to Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction to Dermatology
2.2.1 The Structure of Skin, Hair, and Nails
2.2.2 Hair and Nails
2.2.3 Sweat and Sebaceous Glands
2.2.4 Functions of the Skin
2.3 Common Skin Diseases
2.3.1 Acne: The Most Common Skin Disease
2.3.1.1 Acne: Epidemiology
2.3.1.2 Acne: Causes and Pathogenesis
2.3.1.3 Acne: Treatment
2.3.2 Dermatitis: Inflammation of the Skin
2.3.2.1 Atopic Dermatitis
2.3.2.2 Contact Dermatitis
2.3.2.3 Seborrhoeic Dermatitis
2.3.2.4 Nummular Dermatitis
2.3.2.5 Perioral Dermatitis
2.3.3 Psoriasis: A Complex Multi-factorial Disease
2.3.4 Rosacea: Vascular Instability
2.3.5 Alopecia: Excessive Shedding Of Hair
2.4 Skin Infections: A Serious Healthcare Threat
2.4.1 Bacterial Skin Infections
2.4.2 Fungal Skin Infections
2.4.3 Viral Skin Infections
2.5 Common Skin Treatments
2.5.1 Creams and Semisolid Emulsions
2.5.2 Ointments
2.5.3 Lotions
2.5.4 Solutions
2.5.5 Occlusive Therapy
2.5.6 Cleansing Agents
2.5.7 Powders and Hydrophilic Polymer
2.5.8 Anti-Infective Agents
2.5.9 Anti-Inflammatory Agents
2.6 Phases of Clinical Trials
2.7 Dermatological Drugs: Market Definition in this Report
3. The Global Dermatological Drugs Market, 2016-2026
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation of the Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market in 2015
3.4 The Global Dermatological Drugs Market: Market Forecast 2016-2026
3.5 Dermatological Drugs: Changing Market Shares by Sector 2016-2026
4. The Psoriasis Drugs Market: Market Analysis and Forecast 2016-2026
4.1 Psoriasis Treatments: The Dominance of Biologics
4.1.1 Leading Products in the Psoriasis Drugs Market, 2015
4.2 Psoriasis: Market Trends and Developments, 2016
4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview
4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing
4.2.3 The Disadvantages of Biologics in Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2016-2026
4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2015-2026
4.4 Leading Drugs Used in the Treatment of Psoriasis
4.4.1 Humira (adalimumab) – AbbVie
4.4.1.1 Humira: Historical Sales Analysis, 2010-2015
4.4.1.2 Humira: Sales Forecast 2016-2026
4.4.1.3 Future Prospects for Biosimilar Versions of Humira
4.4.2 Stelara (ustekinumab) – Johnson & Johnson
4.4.2.1 Stelara: Historical Sales Analysis, 2010-2014
4.4.2.2 Stelara: Sales Forecast 2016-2026
4.4.2.3 Intensifying Competition for Stelara
4.4.3 Enbrel (etanercept) – Amgen/ Pfizer/ Takeda
4.4.3.1 Enbrel: Co-Promotions and Marketing Rights
4.4.3.2 Enbrel: Historical Sales Analysis, 2008-2015
4.4.3.2 Enbrel: Patent Expiries and Potential Competition, 2016-2026
4.4.3.4 Enbrel: Sales Forecast 2016-2026
4.4.3.5 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
4.4.3.6 Competition from Other Drugs
4.4.3.7 Biosimilar Competition for Enbrel
4.4.4 Remicade (infliximab) – Johnson & Johnson
4.4.4.1 Remicade: Historical Sales Analysis, 2010-2015
4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2016-2026
4.4.4.3 Remicade: Sales Forecast 2016-2026
4.4.5 Taltz (ixekizumab) – Eli Lily
4.4.5.1 Taltz: Sales Forecast 2016-2026
4.4.6 Otezla (apremilast) – Celgene
4.4.6.1 Otezla: Sales Forecast 2016-2026
4.4.7 Cosentyx (secukinumab) – Novartis
4.4.7.1 Cosentyx: Sales Forecast 2016-2026
4.4.8 Other Psoriasis Drugs
4.4.8.1 Cimzia (certolizumab) – UCB
4.4.8.2 Sorilux (calcipotriene foam) – GSK
4.4.8.3 Other Psoriasis Drugs: Sales Forecast 2016-2026
4.5 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis and Forecast 2016-2026
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products in the Skin Infection Drugs Market, 2015
5.2 Skin Infection Drugs: Market Forecast 2016-2026
5.2.1 Skin Infection Drugs: Changing Market Shares by Leading Drugs 2016-2026
5.3 Leading Drugs Used in the Treatment of Skin Infections
5.3.1 Cubicin (daptomycin) – Cubist Pharmaceuticals/ Merck & Co
5.3.2 Acquisition By Merck & Co
5.3.3 Generic Competition For Cubicin
5.3.4 Cubicin: Sales Forecast 2016-2026
5.3.5 Lifecycle Management Strategies for Cubicin
5.4 Zyvox (linezolid) – Pfizer
5.4.1 Zyvox: Historical Sales Analysis, 2010-2014
5.4.2 Zyvox: Sales Forecast 2016-2026
5.4.3 The Threats to Zyvox Sales from Competing New Drugs
5.5 Canesten (clotrimazole) – Bayer
5.5.1 Canesten: Historical Sales Analysis, 2011-2014
5.5.2 Canesten: Sales Forecast 2016-2026
5.6 Valtrex (valaciclovir) – GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2014
5.6.2 Valtrex: Sales Forecast 2016-2026
5.7 Bactroban (mupirocin) – GSK
5.7.1 Bactroban: Historical Sales Analysis, 2010-2013
5.7.2 Bactroban: Sales Forecast 2015-2026
5.8 Lamisil (terbinafine) – Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2016-2026
5.9 Other Skin Infection Drugs
5.9.1 Dalvance (dalbavancin) – Durata Therapeutics
5.9.2 Jublia (efinaconazole) – Valeant
5.9.3 Kerydin (tavaborole) – Anacor
5.9.4 Sivextro (tedizolid) – Cubist Pharmaceuticals
5.9.5 Zovirax (acyclovir) – Valeant/GSK
5.9.5.1 Valeant Acquires Zovirax In US And Canada
5.9.5.2 Mylan’s Generic Zovirax And Actavis’ Authorised Generic
5.9.6 Other Skin Infection Drugs: Sales Forecast 2016-2025
5.10 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis and Forecast 2016-2026
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products in the Acne Drugs Market, 2015
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise of Combination Therapies in Acne Treatment
6.2.2 Oral Contraceptives in Treating Acne
6.2.3 The Threat of Generic Competition in the Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2015-2026
6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2015-2026
6.4 Leading Drugs in the Acne Drugs Market
6.4.1 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.4.1.1 Epiduo: Sales Forecast 2016-2026
6.4.1.2 Galderma Settlement Agreement over Generic Epiduo
6.4.1.3 Paediatric Approval for Epiduo
6.4.2 Solodyn (minocycline) – Valeant
6.4.2.1 Solodyn: Sales Forecast 2016-2026
6.4.2.2 Antitrust Action Over Solodyn Pay-For-Delay Deals
6.4.2.3 Impax And Medicis Collaborating On Advanced Solodyn
6.4.2.4 Medicis And Lupin Settle
6.4.3 Claravis (isotretinoin) – Teva
6.4.3.1 Claravis: Sales Forecast 2016-2026
6.4.4 Aczone (dapsone) – Allergan
6.4.4.1 Aczone: Sales Forecast 2016-2026
6.4.5 Differin (adapalene) – Galderma/ Nestlé Skin Health
6.4.5.1 Recent Generic Competition to Differin
6.4.5.2 Differin: Sales Forecast 2016-2026
6.4.5.3 Adapalene Gel to be Available OTC in the US
6.4.5.4 Federal Circuit Court Invalidates Differin Patents
6.4.6 Absorica/Epuris (CIP-isotretinoin) – Cipher/ Sun Pharma
6.4.6.1 Absorica/Epuris: Sales Forecast 2016-2025
6.4.7 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.4.7.1 Valeant’s Patent Settlement with Actavis Over Ziana
6.4.7.2 Ziana: Sales Forecast 2016-2026
6.4.8 Doryx (doxycycline) – Actavis/ Mayne Pharma
6.4.8.1 Lifecycle Management Strategies for Doryx
6.4.8.2 Divestment Agreement with Mayne Pharma
6.4.8.3 Generic Competition for Doryx
6.4.8.4 Doryx: Sales Forecast 2016-2026
6.4.9 Other Acne Drugs
6.4.9.1 Acanya (clindamycin/benzoyl peroxide) – Dow / Valeant
6.4.9.1.1 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
6.4.9.1.2 Legal Battles Involving Dow/Valeant, Perrigo, And Watson
6.4.9.2 Amnesteem (isotretinoin) – Mylan
6.4.9.2.1 Amnesteem: Financial Analysis
6.4.9.3 Diane (cyproterone/ethinyl estradiol) – Bayer
6.4.9.4 Duac (clindamycin/benzoyl peroxide) – GlaxoSmithKline
6.4.9.5 Veltin (tretinoin/clindamycin) – GSK
6.4.9.6 Other Acne Drugs: Sales Forecast 2016-2026
6.5 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis and Forecast 2016-2026
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products in the Dermatitis Drugs Market, 2015
7.2 Dermatitis Drugs: Market Forecast 2016-2026
7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2016-2026
7.3 Leading Drugs in the Dermatitis Drugs Market
7.3.1 Bepanthen (dexpanthenol)/ Bepanthol – Bayer
7.3.1.1 Bepanthen: Sales Forecast 2016-2026
7.3.2 Elocon (mometasone) – Merck & Co
7.3.2.1 Elocon: Sales Forecast 2016-2026
7.3.3 Protopic (tacrolimus) – LEO Pharma
7.3.3.1 Protopic Benefits from Expanded Indication
7.3.3.2 Generic Competition For Protopic
7.3.3.3 Protopic: Sales Forecast 2016-2026
7.3.4 Dermovate -GSK
7.3.4.1 Dermovate: Sales Forecast 2016-2026
7.3.5 Other Dermatitis Drugs: Sales Forecast 2016-2026
7.4 Dermatitis Drugs: Market Outlook
8. Leading National Markets for Dermatological Drugs, 2016-2026
8.1 The Dermatological Drugs Market by Region
8.1.1 The Global Distribution of Dermatological Drugs in 2015
8.2 Leading National Markets: Forecast 2016-2026
8.2.1 Changing Market Shares by Region, 2015-2026
8.3 Regional Dermatological Drugs Markets: Analysis and Forecasts, 2015-2026
8.3.1 United States: The Largest Dermatological Drugs Market
8.3.1.1 The Impact of an Expanding Medicare Coverage
8.3.1.2 Legislative Environment Stimulating Biosimilars Market?
8.3.1.3 US Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2 The EU5 Markets: Growth Expected in Each Country
8.3.2.1 EU5 Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2.1.1 EU5 Markets: Changing Market Shares by Country, 2015-2026
8.3.2.2 Germany
8.3.2.2.1 German Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2.3 France
8.3.2.3.1 French Dermatological Drugs Market Forecast 2016-2026
8.3.2.4 UK
8.3.2.4.1 UK Dermatological Drugs Market Forecast 2016-2026
8.3.2.5 Italy
8.3.2.5.1 Italian Dermatological Drugs Market Forecast 2016-2026
8.3.2.6 Spain
8.3.2.6.1 Spanish Dermatological Drugs Market Forecast 2016-2026
8.3.3 Japan
8.3.3.1 The Cost of Treatment in Japan
8.3.3.2 Japanese Pharmaceutical Industry Regulatory Reform
8.3.3.3 Japanese Dermatological Drugs Market Forecast 2016-2026
8.3.4 China
8.3.4.1 Expansion of Healthcare Coverage and Reimbursement in China
8.3.4.2 Improving Public Perception of Dermatology in China
8.4.3.3 Price Controls and the Anhui Model
8.3.4.4 Chinese Dermatological Drugs Market Forecast 2016-2026
8.3.5 India
8.3.5.1 The Effects of the Drug Prices Control Order of 2013
8.3.5.2 India’s Expansion of Healthcare Provision
8.3.5.3 Indian Dermatological Drugs Market Forecast 2016-2026
8.3.6 Brazil
8.3.6.1 The Growth in Brazil’s Healthcare Landscape
8.3.6.2 Clearer Access to Medicines in Brazil
8.3.6.3 Brazilian Dermatological Drugs Market Forecast 2016-2026
8.3.7 Russia
8.3.7.1 Pharma2020 Strategy – Healthcare and Industry Reform
8.3.7.2 Russian Dermatological Drugs Market Forecast 2016-2026
8.3.8 Rest of the World
8.3.8.1 The Rest of the World Dermatological Drugs Market Forecast 2016-2026
9. Leading Companies in the Dermatological Drugs Market, 2016-2026
9.1 Dermatological Drugs – A Rapidly Consolidating Market
9.2 Galderma (Nestle Skin Health S.A.)
9.2.1 Galderma: Dermatological Drugs Portfolio, 2016
9.2.2 Galderma: Recent Developments
9.2.2.1 Nestlé’s Acquisition of Galderma
9.2.2.2 Approval and Launch of Soolantra for Rosacea
9.3 Johnson & Johnson
9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2015
9.3.2 Johnson & Johnson: Dermatological Drug Development
Pipeline, 2016
9.4 AbbVie
9.4.1 AbbVie: Dermatological Drugs Portfolio, 2016
9.5 GlaxoSmithKline (GSK)
9.5.1 GSK: Dermatological Drugs Portfolio, 2016
9.5.3 GlaxoSmithKline (GSK): Recent Developments
9.5.3.1 Business Restructuring Arrangements With Novartis
9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2016
9.6 Pfizer
9.6.1 Pfizer: Dermatological Drugs Portfolio, 2016
9.6.2 Pfizer: Dermatological Drugs Development Pipeline, 2016
9.7 LEO Pharma
9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2016
9.7.2 LEO Pharma: Dermatological Drugs Development Pipeline, 2016
10. Dermatological Drugs: Research and Development Pipeline, 2016-2026
10.1 Innovative Products Currently in Development Will Drive Growth
10.1.1 New Technology in R&D Pipeline Activities
10.1.1.1 Reformulation
10.1.1.2 Combination Treatments
10.1.1.3 New Mechanisms and Drug Delivery Technologies
10.1.1.4 Potential Market Entrants
10.2 Psoriasis Drugs Development Pipeline, 2016
10.2.1 Psoriasis Drugs in Phase 3 Development or Regulatory Approval Stage
10.2.1.1 AMG 827 (brodalumab) – AstraZeneca/ LEO Pharma
10.2.1.2 CF101 (Piclidenoson) – Can-Fite BioPharma
10.2.1.3 CNTO 1959 (guselkumab) – MorphoSys/ Janssen
10.2.1.4 LAS41008 (dimethyl fumarate) – Almirall
10.2.1.5 MK-3222/SCH 900222 (tildrakizumab) – Merck/Sun Pharma
10.2.2 Psoriasis Drugs in Phase 2 Development
10.2.2.1 LY3009104 (baricitinib) – Incyte/ Eli Lilly
10.2.2.2 PH-10 (Rose Bengal) – Provectus Biopharmaceuticals
10.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical Development
10.3 Skin Infection Drugs Development Pipeline, 2016
10.3.1 Drugs in Phase 3 Development for Skin Infections
10.3.1.1 Baxdela (delafloxacin) – Melinta Pharmaceuticals
10.3.1.2 NB-001 – NanoBio Corporation
10.3.1.3 Luliconazole – Topica Pharmaceuticals
10.3.2 Drugs in Phase 2 Development for Skin Infections
10.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
10.4 Acne Drugs Development Pipeline, 2016
10.4.1 Drugs in Phase 3 Development for Acne
10.4.1.1 Duac low dose (clindamycin/ benzoyl peroxide) – GlaxoSmithKline
10.4.1.2 Visonac (photodynamic therapy) – Photocure
10.4.2 Drugs in Phase 2 Development for Acne
10.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne
10.4.4 A Possible Vaccine for Acne
10.5 Dermatitis Drugs Development Pipeline, 2016
10.5.1 Drugs in Phase 3 Development for Dermatitis
10.5.1.1 Toctino (alitretinoin) – GSK
10.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher Pharmaceuticals
10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre Fabre
10.5.1.4 REGN668/SAR231893 (dupilumab) – Regeneron/ Sanofi
10.5.2 Drugs in Phase 2 Development for Dermatitis
10.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
10.6 Other Dermatological Drugs Development Pipeline, 2016
10.6.1 Other Dermatological Drugs: Filed or Recently Launched
10.6.1.1 Actikerall (fluorouracil/salicylic acid) – Almirall
10.6.1.2 Ameluz (5-ALA photodynamic therapy) – Biofrontera
10.6.1.3 Mirvaso (brimonidine) – Galderma
10.6.1.4 Picato (ingenol mebutate) – LEO Pharma
10.6.1.5 Xolair (omalizumab) – Novartis/ Roche
10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2016
10.6.2.1 CD5024 (ivermectin) – Galderma
10.6.2.2 SR-T100 gel (Solanum incanum extract) – G&E Herbal Biotechnology
10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2016
11. Qualitative Analysis of the Dermatological Drugs Market, 2016-2026
11.1 Market Factors Influencing Dermatological Drugs
11.2 SWOT Analysis of the Global Dermatological Drugs Market, 2016-2026
11.2.1 Strengths
11.2.1.1 The High Unmet Clinical Need in Dermatology
11.2.1.2 A Healthy Pipeline of Development-Stage Products
11.2.1.3 Strong Industry-Physician Relationships
11.2.2 Weaknesses
11.2.2.1 Limited Efficacy and Adverse Effects May Impact Product Uptake
11.2.2.2 Patient Adherence – A Major Challenge to Treatment Design
11.2.2.3 Impending Patent Expiries and the Challenges Posed by Generic Competition
11.2.3 Opportunities
11.2.3.1 The High-Growth Sectors in Dermatology
11.2.3.2 Personalised Dermatology: Technological Advances in Genomics
11.2.3.3 Advances in Topical Drug Delivery Methods Offers Product Differentiation
11.2.3.4 Consolidation within Dermatology – Opportunity for Synergistic Growth?
11.2.4 Threats
11.2.4.1 Uncertain Surrounding Reimbursement and Payment Approvals
11.2.4.2 The Rising Cost of Research and Development
11.2.4.3 Downward Pressures on Drug Prices
11.3 Porter’s Five Force Analysis of the Global Dermatological Drugs Market, 2016-2026
11.3.1 Threat of New Entrants
11.3.2 Threat of Substitutes
11.3.3 Rivalry among Competitors
11.3.4 Power of Buyers
11.3.5 Power of Suppliers
12. Conclusions
12.1 Overview of Current Market Conditions and Market Forecast, 2015-2026
12.2 Leading Sectors in Dermatological Drugs in 2015
12.3 Leading Regions in the Dermatological Drugs Market in 2015
12.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2016-2026
12.5 What Does The Future Hold For Dermatological Drugs?
13. Glossary
【レポート販売概要】
■ タイトル：皮膚科治療薬の世界市場予測2016-2026■ 英文：Dermatological Drugs Market Forecast 2016-2026
■ 発行日：2016年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN81920
■ 調査対象地域：グローバル
- Bronchospasm：グローバル臨床試験レビューH1, 2013Bronchospasm Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Bronchospasm Global Clinical Trials Review, H1, 2013" provides data on the Bronchospasm clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bronchospasm. It includes an overview of the trial numbers and their recruitment status as per the sit …
- HVACエアダクトの世界市場2017-2021About HVAC Air Ducts Heating, ventilation, and air conditioning (HVAC) is one of the most energy-intensive systems in commercial and residential buildings. Air ducts are conduits or passages used in HVAC to distribute and ventilate air. Supply air, return air, and exhaust air are the needed airflows in an HVAC system that flow through HVAC air ducts. Ducts commonly also deliver ventilation air alo …
- 世界の臭素市場：市場規模、動向、メーカー動向Scope The report presents a thorough study of bromine, covering both global and regional markets It aims to give a proper picture of the market, as well as its trends, perspectives and opportunities Comprehensive data showing bromine production, consumption, trade statistics and prices are provided (both nationwide and worldwide) Each country’s market overview covers the following: bromine product …
- クラウド・ゲームの世界市場2016-2020About the Cloud Gaming Market The introduction and popularity of PCs and electronic devices and the rise of the internet have led to the development and commercialization of gaming across the globe. Individuals are passionate about interactive entertainment in the form of games, which have different genres and offer different user experiences in a broad variety of platforms. Individuals require pl …
- 世界の整形外科用電動器具（医療機器）市場MediPoint: Orthopedic Power Tools - Global Analysis and Market Forecasts Summary A power tool is a key instrument in the armamentarium of the operating room for many orthopedic surgeries. The adoption rates for orthopedic power tools vary in different regions, mainly due to price sensitivity. Globally, and driven by the orthopedic industry’s continued innovation in cordless battery-powered systems …
- 世界の経腸供給デバイス市場2015The Global Enteral Feeding Devices Industry Report 2015 is a professional and in-depth study on the current state of the Enteral Feeding Devices industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Enteral Feeding Devices market analysis is provided for the international markets including development tr …
- 世界のプロセス安全システム市場動向（2012-2016）TechNavio's analysts forecast the Global Process Safety System market to grow at a CAGR of 11.28 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for safety systems from the Oil and Gas industry. The Global Process Safety System market has also been witnessing the increasing demand of safety system from the APAC region. However, …
- ベビーキャリアの世界市場2016-2020About Baby Carriers Baby carriers provide mobility and hands-free convenience of carrying babies while performing other activities. The global baby carriers market is growing at significant rates in APAC and ROW. An increase in the number of dual-income families and the increased awareness about child health and safety have led to the high demand in these regions. The global market will grow at a …
- コンクリート補強繊維の世界市場：合成繊維、スチール繊維、ガラス繊維、天然繊維、バサルト繊維Concrete fibers are categorized into varied material types based on their functionalities, such as synthetic, steel, glass, natural, and basalt fibers. They possess inherent properties, such as high durability and stiffness, strong impact resistance, and provide concrete with mechanical, chemical, and thermal resistances. Synthetic fibers are advantageous in terms of toughness, and abrasion & chem …
- Repsol S.A.：石油・ガスバリューチェーン分析レポート2013Repsol S.A. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Repsol S.A." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Repsol S.A.”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines the company’s business …
- イオン交換樹脂の世界市場2015-2019About ion exchange resins Ion exchange resins belong to a category of polymers that have the ability to replace ions present in solutions with their own. This ability is commonly exhibited by naturally occurring substances such as proteins, celluloses, soil particles, and live cells. However, this exchange of ions does not alter the physical structure of the material. Ion exchangers belong to a cl …
- JSC Latvijas Gaze：石油・ガスバリューチェーン分析レポート2013JSC Latvijas Gaze Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "JSC Latvijas Gaze" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “JSC Latvijas Gaze”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines the …
- Black Ridge Oil & Gas Inc.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Black Ridge Oil & Gas Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Black Ridge Oil & Gas Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essent …
- シリアルバー（食品）市場動向（～2017）：スペインSynopsis The report presents detailed data on consumption trends in the Cereal Bars category in Spain, analyzing consumption volumes and values at segment level. It also provides indispensable data on distribution channels along with latest industry news and mergers & acquisitions (of Bakery & Cereals market). Furthermore the report enables readers to examine the components of change in the indust …
- 放射免疫測定（RIA）の世界市場：放射免疫測定試薬、放射免疫測定キット、放射免疫測定装置This report on the global radioimmunoassay market is analysed and segmented on the basis of type, application, end user, and region. It analyzes the competitive developments, such as alliance, joint venture, and merger & acquisition, in the global radioimmunoassay market. This market is also analyzed with an explicit focus on the high-growth applications and fastest-growing market segments. The te …
